报价延迟最少15分钟:2025/11/22 16:43 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.11 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.64/-1.16
|
|
企业价值
94.35M
|
| 资产负债 |
|
每股账面净值
3.33
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
25.98M
|
|
每股收益
0.47
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. |
